What is Werewolf Therapeutics Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Werewolf Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was 2.72.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Werewolf Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.
The historical rank and industry rank for Werewolf Therapeutics's Cash-to-Debt or its related term are showing as below:
HOWL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 2.49 Med: 9.13 Max: 83.51
Current: 2.72
During the past 5 years, Werewolf Therapeutics's highest Cash to Debt Ratio was 83.51. The lowest was 2.49. And the median was 9.13.
Werewolf Therapeutics Cash-to-Debt Historical Data
The historical data trend for Werewolf Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Werewolf Therapeutics Cash-to-Debt Chart
|
Werewolf Therapeutics Annual Data
|
|
Trend |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
5.71 |
36.43 |
10.06 |
8.81 |
2.59 |
|
Werewolf Therapeutics Quarterly Data
|
|
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
2.78 |
2.60 |
2.49 |
2.59 |
2.72 |
Competitive Comparison of Werewolf Therapeutics's Cash-to-Debt
For the Biotechnology subindustry, Werewolf Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Werewolf Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Werewolf Therapeutics's Cash-to-Debt falls into.
Werewolf Therapeutics Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Werewolf Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Werewolf Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Werewolf Therapeutics (Werewolf Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
200 Talcott Avenue, 2nd Floor, Watertown, MA, USA, 02472
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
Executives
| Ra Capital Healthcare Fund Lp |
director, 10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Luke Evnin |
director |
THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116 |
| Meeta Chatterjee |
director |
C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142 |
| Michael A. Sherman |
director |
3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906 |
| Chulani Karunatilake |
officer: Chief Technology Officer |
1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138 |
| Reid Leonard |
officer: Chief Operating Officer |
1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138 |
| Mpm Oncology Innovations Fund Lp |
10 percent owner |
450 KENDALL STREET, CAMBRIDGE MA 02142 |
| Longwood Fund Iii Gp, Llc |
10 percent owner |
800 BOYLSTON ST, SUITE 1555, BOSTON MA 02199 |
| Derek Dirocco |
director |
535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
| Moshe Arkin |
10 percent owner |
6 HACHOSHLIM ST., HERZELIA L3 4672406 |
| Alon Lazarus |
director, 10 percent owner |
C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421 |
| Daniel J Hicklin |
director, 10 percent owner, officer: See Remarks |
|
| Sphera Funds Management Ltd. |
10 percent owner |
4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520 |
| Sphera Global Healthcare Management Lp |
10 percent owner |
4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520 |
| Sphera Global Healthcare Gp Ltd. |
10 percent owner |
4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520 |
Werewolf Therapeutics (Werewolf Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HOWL has been successfully added to your